Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

Background: Unboosted atazanavir with raltegravir has been investigated at 300mg twice daily showing frequent hyperbilirubinemia and selection of resistance-associated mutations.

Objectives: Atazanavir 200mg twice daily could increase tolerability and plasma exposure.

Study Design: Patients on atazanavir/raltegravir (200/400 twice daily), with self-reported adherence >95% and no concomitant interacting drugs were retrospectively evaluated.

Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.

As the risk of tenofovir-associated renal toxicity has been found to be proportional to the drug plasma concentration, our aim was to measure the determinants of tenofovir plasma exposure in HIV-positive patients with normal renal function. A cross-sectional analysis was conducted in HIV-positive patients chronically receiving tenofovir-containing highly active antiretroviral therapies (HAARTs). Patients on tenofovir-containing antiretroviral regimens, presenting 22 to 26 h after drug intake, having estimated glomerular filtration rates above 60 ml/min, reporting high adherence to antiretroviral medications (above 95% of the doses), and signing a written informed consent were included.

[Treatment of chronic hepatitis with interferon-beta].

Thirty-five patients suffering from chronic viral hepatitis were treated with beta-IFN during two periods: 22 during 1991 and 13 in 1992. Patients in the first group were treated with a dose of 3 MUI beta-IFN three times a week for six months with a follow-up of 1 year; those patients treated during 1992 received the same dose but over a period of 12 months. The results confirm a satisfactory response (33%) and a good drug tolerability in patients enrolled in 1991.

[Cefixime. Microbiologic, kinetic and clinical profile].

The microbiological, kinetic and clinical profile of cefixime, a IIIrd generation cephalosporin, administered orally, is presented. Cefixime is highly active versus Gram-negative aerobic bacteria while, with respect to Gram-positive bacteria, it is only active against Str. pneumoniae, Str.